Correction: The Synthetic α-Bromo-2′,3,4,4′-Tetramethoxychalcone (α-Br-TMC) Inhibits the JAK/STAT Signaling Pathway

In Figure 5, some of the graphs are missing numbers on the y-axis. Please see the corrected Figure 5 here.

Figure 5. α-Br-TMC exerts distinct effects in normal and cancer cells.

Ba/F3 (A), its caSTAT5-transformed counterpart Ba/F3-1*6 (B) and human leukemic K562 (C) cells were treated 90 minutes with 0.2 µM TSA, 10 µM α-Br-TMC or 1 µM Imatinib. Ba/F3 cells (A) were stimulated with 5 ng/mL IL-3 after an initial 30 minute drug pre-treatment (hence subjected to a 60 minute IL-3 stimulation). DMSO (vehicle) final concentration was adjusted to 0.02% in all conditions. Expression of STAT5-dependent (Cis, Osm, c-Myc, Pim-1) and -independent (JunB, c-Fos, 36b4) genes was analyzed by quantitative RT-PCR. Gene expression data were normalized to mouse ribosomal S9 (A, B) or to human Lamin A/C (LMNA) (C) housekeeping gene-encoded mRNAs. (A, B) Normalized data are presented with adjusted Y-axis scale for a direct comparison of mRNA levels in the respective normal and transformed Ba/F3 and Ba/F3-1*6 cell lines.